NTLA stock news

NTLA stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

17 wire items

2026-10-29 12:00:00 UTC#537087newconfirmednews

Intellia Therapeutics to host Nov. 12 webcast on lonvo-z clinical data and HAE commercial launch plans

tradingviewimportance 0.40trust 0.80Intellia Therapeutics, Inc. +0.30lonvo-z +0.30American College of Allergy, Asthma & Immunology 0+2 entities

2026-10-07 13:01:00 UTC#425760newconfirmednews

Barclays initiates Intellia Therapeutics (NTLA) at Underweight

dow_jonesimportance 0.40trust 0.70Intellia Therapeutics, Inc. -0.40Barclays PLC 0

2026-10-05 10:47:27 UTC#412720newconfirmednews

Ark Invest weekly update: Cathie Wood increases positions in Nvidia and Intellia, reduces AMD holdings

seeking alphaimportance 0.30trust 0.70ARK Investment Management LLC 0NVIDIA Corporation +0.40Intellia Therapeutics, Inc. +0.30+2 entities

2026-09-14 22:01:31 UTC#310405duplicateconfirmednews

Intellia Therapeutics (NTLA) HAE gene therapy FDA approval expected by March 10

quartrimportance 0.30trust 0.50Intellia Therapeutics, Inc. +0.60

2026-09-14 21:13:29 UTC#310220newconfirmednews

Intellia Therapeutics advances HAE and TTR gene editing therapies with FDA review underway

quartrimportance 0.40trust 0.50Intellia Therapeutics, Inc. +0.50

2026-09-08 12:55:08 UTC#280846newconfirmednews

Intellia Therapeutics hereditary angioedema therapy granted FDA priority review

seeking alphaimportance 0.60trust 0.70Intellia Therapeutics, Inc. +0.70Food and Drug Administration +0.50

2026-09-07 11:22:09 UTC#276000newconfirmednews

Intellia Therapeutics secures $400M term loan from OrbiMed and grants 163,100 RSUs to new hires

tradingviewimportance 0.50trust 0.70Intellia Therapeutics, Inc. +0.30OrbiMed Advisors LLC +0.20lonvo-z +0.40

2026-09-04 12:59:15 UTC#268437newconfirmednews

Intellia Therapeutics secures $400 million loan facility

seeking alphaimportance 0.40trust 0.70Intellia Therapeutics, Inc. +0.20

2026-08-25 13:29:00 UTC#217754newconfirmednews

Citizens maintains $30.00 price target on Intellia Therapeutics (NTLA)

dow_jonesimportance 0.30trust 0.60Intellia Therapeutics, Inc. 0Citizens Financial Group, Inc. 0

2026-08-07 12:35:00 UTC#144877updateconfirmednews

Evercore ISI raises Intellia Therapeutics (NTLA) price target to $24 from $16, upgrades to Outperform

dow_jonesimportance 0.40trust 0.70Intellia Therapeutics, Inc. +0.50Evercore ISI Group 0

2026-08-07 12:30:21 UTC#144851newconfirmednews

Intellia Therapeutics upgraded at Evercore ISI citing nex-z hypothesis

seeking alphaimportance 0.40trust 0.70Intellia Therapeutics, Inc. +0.40Evercore ISI Group +0.40nex-z +0.40

2026-08-06 20:36:05 UTC#140210duplicateconfirmednews

Intellia Therapeutics reaffirms cash runway through 2028, targets H1 2027 US launch for lonvo-z

seeking alphaimportance 0.30trust 0.70Intellia Therapeutics, Inc. +0.30lonvo-z +0.40

2026-08-06 20:24:15 UTC#140182newconfirmednews

Intellia Therapeutics average analyst price target cut to $25.56, 133% upside implied

tradingviewimportance 0.30trust 0.70Intellia Therapeutics, Inc. -0.10

2026-08-06 13:32:08 UTC#137837newconfirmednews

Intellia Therapeutics Q2 adjusted loss of $0.80/share matches estimates; revenue of $7.66M misses $13.90M forecast

reutersimportance 0.40trust 0.90Intellia Therapeutics, Inc. -0.40

2026-08-06 13:31:35 UTC#137917newconfirmednews

Intellia Therapeutics reports phase III progress for HAE and ATTR, $628.4M cash runway through 2028

quartrimportance 0.40trust 0.60Intellia Therapeutics, Inc. +0.50

2026-08-05 15:39:15 UTC#131039newconfirmednews

Intellia Therapeutics Q2 2026 Earnings Preview

seeking alphaimportance 0.30trust 0.60Intellia Therapeutics, Inc. 0

2026-07-10 12:39:00 UTC#19900newconfirmednews

Wedbush Raises Intellia Therapeutics Price Target to $17 from $12, Maintains Neutral

dow_jonesimportance 0.30trust 0.70Intellia Therapeutics, Inc. +0.30Wedbush Securities Inc. +0.30